General Announcement::Glenmark receives marketing approval for Ryaltris nasal spray in 13 countries

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
30-Sep-2021 13:35:13
Status
New
Announcement Sub Title
Glenmark receives marketing approval for Ryaltris nasal spray in 13 countries
Announcement Reference
SG210930OTHRMZZT
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
30/09/2021 17:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark receives marketing approval for Ryaltris an innovative combination nasal spray in 13 countries across the EU and UK

Attachments

SGX_PR_30092021.pdf
Total size =568K